Literature DB >> 9144748

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.

J Alam1, S Goelz, P Rioux, J Scaramucci, W Jones, A McAllister, M Campion, M Rogge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9144748     DOI： 10.1023/a:1012128406432

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  12 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.

Authors:  M Asif A Siddiqui; Keri Wellington
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study.

Authors:  M Sandberg-Wollheim; C Bever; J Carter; M Färkkilä; B Hurwitz; Y Lapierre; P Chang; G S Francis
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

4.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta 1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers.

Authors:  E C Borden
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

6.  Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta 1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers.

Authors:  S Fumero
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

Review 7.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.

Authors:  Donald E Mager; William J Jusko
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 9.  Interferon-beta treatment for multiple sclerosis.

Authors:  Robert A Bermel; Richard A Rudick
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches.

Authors:  Cedric E Bobst; Rinat R Abzalimov; Damian Houde; Marek Kloczewiak; Rohin Mhatre; Steven A Berkowitz; Igor A Kaltashov
Journal:  Anal Chem       Date:  2008-08-27       Impact factor: 6.986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.